BridgeBio Pharma BBIO PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's PP&E (net)?
- BridgeBio Pharma (BBIO) reported PP&E (net) of $4.94M in Q1 2026.
- How has BridgeBio Pharma's PP&E (net) changed year-over-year?
- BridgeBio Pharma's PP&E (net) decreased by 26.2% year-over-year, from $6.7M to $4.94M.
- What is the long-term trend for BridgeBio Pharma's PP&E (net)?
- Over 5 years (2020 to 2025), BridgeBio Pharma's PP&E (net) has grown at a -23.4% compound annual growth rate (CAGR), from $20.33M to $5.37M.
- What does PP&E (net) mean?
- The net value of the company's physical assets like buildings and equipment after accounting for wear and tear.
- How do you interpret PP&E (net)?
- An increase suggests capital investment in infrastructure, while a decrease may reflect depreciation or asset divestment.
- How does PP&E (net) compare across companies?
- Lower for companies that outsource manufacturing compared to those with significant internal production capabilities.